Transient Ischemic Attack
Neurological
Transient Ischemic Attack is treated with 3 medications in our database, including Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg, Aspirin and Extended-Release Dipyridamole, ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE. 3 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Boehringer Ingelheim. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Transient Ischemic Attack treatment below.
What help exists for Transient Ischemic Attack
8
drugs indexed
2
with copay cards
2
with patient assistance
0
open travel grants
Every item below links to the manufacturer's or charity's own portal. RxCopays does not take referral fees.
Drugs used to treat Transient Ischemic Attack
8 totalMicardis
telmisartan Β· Boehringer Ingelheim
ππTelmisartan
telmisartan Β· Boehringer Ingelheim
ππBRILINTA
Ticagrelor
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE
Aspirin and Extended-Release Dipyridamole Β· Boehringer Ingelheim
ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE
ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE Β· Boehringer Ingelheim
TICAGRELOR
Ticagrelor
PRAVASTATIN SODIUM
PRAVASTATIN SODIUM
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg
Boehringer Ingelheim
π = copay card Β· π = patient assistance program
Prior authorization patterns for Transient Ischemic Attack drugs
Aggregated from CMS SPUF + commercial PBM formularies. Specific rules vary by plan; confirm with your insurer.
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
β Medicare Part D | β | β | β |
Showing 10 of 15 PA rules for Transient Ischemic Attack drugs. View individual drug pages for complete PA detail.